h-hydrogen

Zinc transporter 8 (ZnT8) is a recently identified major autoantigen in type 1 diabetes, and autoantibodies to ZnT8 (ZnT8A) are new markers for disease prediction and diagnosis. Here we report the results of the first international proficiency evaluation of ZnT8A assays by the Diabetes Antibody Standardization Program (DASP).

After a pilot workshop in 2007, an expanded ZnT8A workshop was held in 2009, with 26 participating laboratories from 13 countries submitting results of 63 different assays. ZnT8A levels were measured in coded sera from 50 patients with newly diagnosed type 1 diabetes and 100 blood donor controls. Results were analyzed comparing area under the ROC curve (ROC-AUC), sensitivity adjusted to 95% specificity (AS95), concordance of sample ZnT8A positive or negative designation, and autoantibody levels.

ZnT8A radio binding assays (RBAs) based on combined immunoprecipitation of the 2 most frequent ZnT8 COOH-terminal domain polymorphic variants showed a median ROC-AUC of 0.848 [interquartile range (IQR) 0.796–0.878] and a median AS95 of 70% (IQR 60%–72%). These RBAs were more sensitive than assays using as antigen either 1 ZnT8 variant only or chimeric constructs joining NH₂- and COOH-terminal domains, assays based on immunoprecipitation and bioluminescent detection, or assays based on immunofluorescent staining of cells transfected with full-length antigen.

The DASP workshop identified immunoprecipitation-based ZnT8A assays and antigen constructs that achieved both a high degree of sensitivity and specificity and were suitable for more widespread clinical application.

We analyzed serial data in patients with clinically stable monoclonal gammopathy to determine the total variation of serum M-spikes [measured with serum protein electrophoresis (SPEP)], urine M-spikes [measured with urine protein electrophoresis (UPEP)], and monoclonal serum free light chain (FLC) concentrations measured with immunoassay.

Patients to be studied were identified by (a) no treatment during the study interval, (b) no change in diagnosis and <5 g/L change in serum M-spike over the course of observation; (c) performance of all 3 tests (SPEP, UPEP, FLC immunoassay) in at least 3 serial samples that were obtained 9 months to 5 years apart; (d) serum M-spike ≥10 g/L, urine M-spike ≥200 mg/24 h, or clonal FLC ≥100 mg/L. The total CV was calculated for each method.

Among the cohort of 158 patients, 90 had measurable serum M-spikes, 25 had urine M-spikes, and 52 had measurable serum FLC abnormalities. The CVs were calculated for serial SPEP M-spikes (8.1%), UPEP M-spikes (35.8%), and serum FLC concentrations (28.4%). Combining these CVs and the interassay analytical CVs, we calculated the biological CV for the serum M-spike (7.8%), urine M-spike (35.5%), and serum FLC concentration (27.8%).

The variations in urine M-spike and serum FLC measurements during patient monitoring are similar and are larger than those for serum M-spikes. In addition, in this group of stable patients, a measurable serum FLC concentration was available twice as often as a measurable urine M-spike.

Background: Assays for IgG antibodies against deamidated gliadin (IgG-anti-dGli) are comparable in exhibit with tests detecting IgA antibodies against accumulation transglutaminase (IgA-anti-tTG) in diagnosing celiac disorder (CD). IgA-anti-tTG are stay away from in IgA deficiency, a stipulation much associated with CD. In IgA deficiency, IgG-anti-tTG, which from a take down entire diagnostic accuracy, are routinely exact. We examined whether IgG-anti-dGli would be advantageous for diagnosing CD in patients with IgA deficiency.

Methods: We feigned 34 IgA-deficient CD patients, 185 IgA-competent newly diagnosed children with CD, 316 children without CD, 400 mature blood donors, and 6 resolve IgA-deficient individuals without CD. Anti-dGli and anti-tTG were modulated by ELISA, and endomysium antibodies (EmA) were sedate by immunofluorescence on butt esophagus (IgA as swell as IgG regal for all antibodies). We premeditated diagnostic sensitivity (percentage of patients chiefly cutoff with 95% CIs) according to age-specific cutoffs for 95% diagnostic specificity and according to cutoffs proposed by the maker of the assays.

Results: No IgA-deficient CD patients were pontifical for any IgA-based antibody assay. Diagnostic tenderness of IgG-anti-tTG was 91.2% (95% CI 76.3%–97.7%) according to age-specific cutoffs and 82.4% (66.1%–92.0%) according to maker cutoffs. The diagnostic sensitiveness of IgG-EmA was 75.8% (58.8%–87.4%) and the warmth of IgG-anti-dGli was 88.2% (72.8%–95.9%) according to both cutoffs.

Conclusions: IgG-anti-dGli and IgG-anti-tTG possess comparable diagnostic sensitivities for IgA-deficient celiac patients. IgG-anti-dGli may be of use for diagnosing CD in IgA-deficient patients.